|
Compound class:
Peptide
Comment: ADP355 is an adiponectin receptor agonist. It is a peptide with sequence derived from the endogenous agonist adiponectin [3-4].
|
|
|||||||||||||||||
| References |
|
1. Barbalho SM, Méndez-Sánchez N, Fornari Laurindo L. (2023)
AdipoRon and ADP355, adiponectin receptor agonists, in Metabolic-associated Fatty Liver Disease (MAFLD) and Nonalcoholic Steatohepatitis (NASH): A systematic review. Biochem Pharmacol, 218: 115871. [PMID:37866803] |
|
2. Kumar P, Smith T, Rahman K, Thorn NE, Anania FA. (2014)
Adiponectin agonist ADP355 attenuates CCl4-induced liver fibrosis in mice. PLoS One, 9 (10): e110405. [PMID:25310107] |
|
3. Otvos L, Surmacz E. (2012)
Adiponectin receptor agonists and methods of use. Patent number: WO2012142142A2. Assignee: Temple Univ School of Medicine. Priority date: 11/04/2012. Publication date: 18/10/2012. |
|
4. Wang H, Zhang H, Zhang Z, Huang B, Cheng X, Wang D, la Gahu Z, Xue Z, Da Y, Li D et al.. (2016)
Adiponectin-derived active peptide ADP355 exerts anti-inflammatory and anti-fibrotic activities in thioacetamide-induced liver injury. Sci Rep, 6: 19445. [PMID:26777428] |